← Dashboard
Sep 02, 2026 10:14 PM ET
Signal
FDA/Bio
Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome
Phase 3 Aspire results provide pivotal efficacy data for Angelman Syndrome treatment.
What changed
Phase 3 Aspire results provide pivotal efficacy data for Angelman Syndrome treatment.
Why it matters
Phase 3 Aspire results provide pivotal efficacy data for Angelman Syndrome treatment. — impact context not separately stored; see What changed.
Sources
eodhd
Related signals
In reversal, American Cancer Society urges routine prostate cancer screening →
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →
PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →